戻る Agenda
On-Demand: Clinical, Clinical Operations, Pharmacovigilance and Data
Learning Objective : To better understand the regulatory enviroment in China To be updated with the latest progress of regulations related to clinical trials in China To better plan the clinical development strategy in a dynamic environment in China
Speaker(s)
As one of the great consequences of drug regulatory reforms, more clinical trials with higher quality are coming in China
Jianqing Chang, DrMed
Tigermed Consulting Ltd., China
Vice President, Drug Regulatory Policy
Establishing New Paradigm – Drug Safety Regional Hubs in Pfizer
Marcin Kruk, PHARMD, PHD
Pfizer, Poland
Senior Director